This is the authors' abstract. We don't add key points for this paper.
The production and consumption of CFC-12 (dichlorodifluoromethane; CCl 2 F 2 ), a major ozone-depleting substance and potent greenhouse gas, were globally phased out by 2010 under the Montreal Protocol. Observation-based (top-down) verification of this phase-out requires quantification of the CFC-12 emissions using atmospheric observations, which have been notably lacking post-2020 for China. In this study, 6814 new high-frequency in situ atmospheric observations of CFC-12 from three Chinese stations in 2024 were analyzed. Combining these observations with inverse modeling, we quantified China’s most recent CFC-12 emissions and revealed a 72% decline, from 12.7 ± 2.2 gigagrams per year (Gg yr –1 ) in 2016 to 3.6 ± 0.8 Gg yr –1 in 2024. We also developed a new bottom-up inventory, which generally reconciles the discrepancy between observation-based estimates and previous inventories. From a global perspective, this study provides the first country-specific, observation-based estimates of CFC-12 emissions for 2024, accounting for 22.6% of the global CFC-12 emissions. In contrast, for other countries, no observation-based CFC-12 emissions exist, or only a few pre-2022 data are available. Approximately three-quarters (77.4%) of global CFC-12 emissions remain unattributed. These findings highlight both China’s success in mitigating CFC-12 emissions, contributing to ozone layer protection and climate mitigation, and the need for enhanced emission quantification across other regions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: